UK Competition Regulator Steps Up Hydrocortisone Probe
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.
You may also be interested in...
King Pharmaceuticals and Auden Mckenzie have been accused by the UK’s competition regulator of sharing out the supply of nortriptyline 10mg and 25mg tablets, in a case that also implicates Alissa and Lexon for exchanging commercially-sensitive information as part of an effort to drive up prices.
Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.
The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.